The The Correlation Between Treatment Duration with Platelet Lymphocyte Ratio (PLR) and Monocyte Lymphocyte Ratio (MLR) In Pulmonary Tuberculosis Patients In Jambi City

Elsi Indah Putri; Rd. Mustopa; Sarinah Siregar

doi:10.35910/icohpj.v5i0.1110

Elsi Indah Putri Departement of Medical Laboratory Technology, Politeknik Kesehatan Kementerian Kesehatan Jambi, Indonesia
Rd. Mustopa Departement of Medical Laboratory Technology, Politeknik Kesehatan Kementerian Kesehatan Jambi, Indonesia
Sarinah Siregar Departement of Medical Laboratory Technology, Politeknik Kesehatan Kementerian Kesehatan Jambi, Indonesia

DOI: https://doi.org/10.35910/icohpj.v5i0.1110

Keywords: Platelet Lymphocyte Ratio, Monocyte Lymphocyte Ratio, Pulmonary tuberculosis, treatment duration, inflammatory biomarkers

Abstract

Background: Pulmonary tuberculosis (TB) is still a major health concern worldwide. The platelet‑lymphocyte ratio and monocyte‑lymphocyte ratio are simple blood-based markers of systemic inflammation that may track treatment response. This study examined whether a longer course of anti-TB therapy is linked to lower PLR and MLR values in patients from Jambi City.

Methods: A cross-sectional analysis involved 30 smear-positive pulmonary TB patients recruited from community health centres. Fifteen patients had received treatment for less than 2 months, and fifteen for more than 2 months. PLR and MLR were calculated from complete blood counts. Group differences were tested with the independent‑samples t-test.

Results: The mean PLR was 142 in the < 2-month group and 137 in the > 2-month group. Mean MLR values were 0.36 and 0.34, respectively. Although both markers trended downward with longer therapy, neither difference reached statistical significance (PLR p = 0.42; MLR p = 0.48)

Conclusion: In this study, PLR and MLR did not differ significantly between early-phase and later-phase treatment groups, suggesting that these ratios may not be sufficiently sensitive to short-term changes during anti-TB therapy. Larger longitudinal studies are needed to clarify their utility as inflammatory biomarkers in pulmonary TB management.